1176 related articles for article (PubMed ID: 33608497)
1. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
2. Targeting innate sensing in the tumor microenvironment to improve immunotherapy.
Liu Z; Han C; Fu YX
Cell Mol Immunol; 2020 Jan; 17(1):13-26. PubMed ID: 31844141
[TBL] [Abstract][Full Text] [Related]
3. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
Uche IK; Kousoulas KG; Rider PJF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
[TBL] [Abstract][Full Text] [Related]
5. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.
Pan C; Liu H; Robins E; Song W; Liu D; Li Z; Zheng L
J Hematol Oncol; 2020 Apr; 13(1):29. PubMed ID: 32245497
[TBL] [Abstract][Full Text] [Related]
6. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
7. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies.
Ajina R; Zahavi DJ; Zhang YW; Weiner LM
Semin Cancer Biol; 2020 Oct; 65():28-37. PubMed ID: 31866479
[TBL] [Abstract][Full Text] [Related]
8. Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition.
Kim HJ; Cantor H; Cosmopoulos K
Trends Immunol; 2020 Oct; 41(10):948-963. PubMed ID: 32976740
[TBL] [Abstract][Full Text] [Related]
9. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang Q; Xie B; Liu S; Shi Y; Tao Y; Xiao D; Wang W
Front Immunol; 2021; 12():773168. PubMed ID: 35003090
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation.
Liu C; Wang M; Xu C; Li B; Chen J; Chen J; Wang Z
J Immunol Res; 2021; 2021():8970173. PubMed ID: 34877360
[TBL] [Abstract][Full Text] [Related]
11. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
12. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
14. Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors.
Ahn R; Ursini-Siegel J
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807608
[TBL] [Abstract][Full Text] [Related]
15. Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance.
Weng CY; Kao CX; Chang TS; Huang YH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514004
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors.
Li Z; Deng J; Sun J; Ma Y
Front Immunol; 2020; 11():595207. PubMed ID: 33240283
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
[TBL] [Abstract][Full Text] [Related]
18. Immune metabolism in PD-1 blockade-based cancer immunotherapy.
Kumar A; Chamoto K
Int Immunol; 2021 Jan; 33(1):17-26. PubMed ID: 32622347
[TBL] [Abstract][Full Text] [Related]
19. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
Bader JE; Voss K; Rathmell JC
Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
[TBL] [Abstract][Full Text] [Related]
20. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
Zeng Z; Yang B; Liao Z
Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]